These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2396063)

  • 1. [The selective financing of drugs].
    Ortún Rubio V
    Rev Enferm; 1990; 13(143-4):13-5. PubMed ID: 2396063
    [No Abstract]   [Full Text] [Related]  

  • 2. Reforming patient assistance programs: perfect world meets real world.
    Weinberg M
    Health Aff (Millwood); 2009; 28(3):839-42. PubMed ID: 19414895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient assistance programs: information is not our enemy.
    Choudhry NK; Lee JL; Agnew-Blais J; Corcoran C; Shrank WH
    Health Aff (Millwood); 2009; 28(3):843-4. PubMed ID: 19414896
    [No Abstract]   [Full Text] [Related]  

  • 4. Voluntary patient assistance programs: additional federal oversight unwarranted.
    Johnson K
    Health Aff (Millwood); 2009; 28(3):835-8. PubMed ID: 19414894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Medicare prescription drug benefit: issues and options.
    Cubanski J
    Issue Brief (Commonw Fund); 2003 Apr; (618):1-8. PubMed ID: 12693394
    [No Abstract]   [Full Text] [Related]  

  • 6. Practitioners and health policy. Case of the Ontario Drug Benefit Plan.
    Shortt SE
    Can Fam Physician; 1995 Dec; 41():2053-60, 2070-6. PubMed ID: 8680287
    [No Abstract]   [Full Text] [Related]  

  • 7. When success sours: PBMs under scrutiny.
    Carroll J
    Manag Care; 2002 Sep; 11(9):20-6. PubMed ID: 12369344
    [No Abstract]   [Full Text] [Related]  

  • 8. Adverse selection in private, stand-alone drug plans and techniques to reduce it.
    Boccuti C; Moon M
    Policy Brief Commonw Fund; 2003 Oct; (681):1-9. PubMed ID: 14562798
    [No Abstract]   [Full Text] [Related]  

  • 9. The draft pharmaceutical policy: the weakest link.
    Desrosiers G
    Perspect Infirm; 2005; 2(4):8-11. PubMed ID: 15816423
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmaceuticals issue brief: pharmaceutical assistance programs: year end report--2004.
    Seay M
    Issue Brief Health Policy Track Serv; 2004 Dec; ():1-26. PubMed ID: 15724309
    [No Abstract]   [Full Text] [Related]  

  • 11. Outpatient drugs: Medicare's new benefit.
    Grimaldi PL
    Nurs Manage; 1988 Sep; 19(9):15-7. PubMed ID: 3050642
    [No Abstract]   [Full Text] [Related]  

  • 12. Prescription drug pricing: the consumer perspective.
    Searing A
    N C Med J; 2003; 64(6):300-2. PubMed ID: 14983625
    [No Abstract]   [Full Text] [Related]  

  • 13. Healing an ailing pharmaceutical system: prescription for reform for United States and Canada.
    Gaffney A; Lexchin J; ;
    BMJ; 2018 May; 361():k1039. PubMed ID: 29773533
    [No Abstract]   [Full Text] [Related]  

  • 14. Industry warily eyes new Medicare drug plan.
    Vastag B
    Nat Biotechnol; 2006 Feb; 24(2):120. PubMed ID: 16465141
    [No Abstract]   [Full Text] [Related]  

  • 15. Oncology pharmaceutical funding in New Zealand: a different approach and a proposal.
    Beatty PA; Laking GR
    J Oncol Pract; 2015 May; 11(3):249-51. PubMed ID: 25829524
    [No Abstract]   [Full Text] [Related]  

  • 16. Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia.
    Morgan S; McMahon M; Greyson D
    Health Policy; 2008 Aug; 87(2):133-45. PubMed ID: 18295927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PHARMAC and long-acting insulin analogues: a poor man's insulin pump--but not available to the poor man.
    Krebs J
    N Z Med J; 2005 Aug; 118(1221):U1641. PubMed ID: 16138177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Finance issue brief: mandated benefits: off-label drug coverage requirements: year end report-2003.
    Plaza CI
    Issue Brief Health Policy Track Serv; 2003 Dec; ():1-9. PubMed ID: 14870745
    [No Abstract]   [Full Text] [Related]  

  • 19. The need for health care reform.
    Mossinghoff GJ
    Health Syst Rev; 1994; 27(3):5-6. PubMed ID: 10134516
    [No Abstract]   [Full Text] [Related]  

  • 20. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
    Pavenik N
    Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.